Barrett Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Barrett Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.9M	Buy	4,152 +14	+0.3%	+$8.86K	0.12%	78
2021 Q4	$2.61M	Buy	4,138 +693	+20%	+$426K	0.1%	83
2021 Q3	$2.08M	Sell	3,445 -116	-3%	-$72K	0.1%	82
2021 Q2	$1.99M	Buy	3,561 +275	+8%	+$139K	0.09%	84
2021 Q1	$1.55M	Buy	3,286 +316	+11%	+$154K	0.08%	92
2020 Q4	$1.44M	Buy	2,970 +94	+3%	+$50.7K	0.08%	86
2020 Q3	$1.61M	Buy	2,876 +461	+19%	+$280K	0.1%	79
2020 Q2	$1.51M	Buy	2,415 +915	+61%	+$519K	0.1%	73
2020 Q1	$732K	Hold	1,500	–	–	0.06%	92
2019 Q4	$563K	Buy	+1,500	New	+$505K	0.03%	106
2018 Q1	–	Sell	-75	Closed	-$28K	–	398
2017 Q4	$28K	Buy	+75	New	+$30.4K	﹤0.01%	292

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barrett Asset Management's REGN Position: Q1 2022 in Review

Barrett Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.34% in Q1 2022, buying an estimated $8.86K and bringing the position to 4,152 shares worth $2.9M. The position accounts for 0.12% of the portfolio, ranked #78.

Barrett Asset Management first reported a position in REGN in Q4 2017 and has held it in 11 quarters since. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Barrett Asset Management held 4,152 shares of Regeneron Pharmaceuticals worth $2.9M as of Q1 2022.
Barrett Asset Management bought 14 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $8.86K.
Regeneron Pharmaceuticals made up 0.12% of Barrett Asset Management's portfolio in Q1 2022, its #78 holding.
Barrett Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 11 quarters since.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Barrett Asset Management's 13F filing for Q1 2022, filed 16 May 2022.